home Go to Doctors Page
ScienceBased Health
1 888 433 4726
  • Doctor
  • Consumer
Facebook Twitter

Free Shipping with Auto-Delivery & Savings up to 20% with a Package Plan

more +
Auto-Delivery & Free Shipping!
Save money and add convenience! Your product(s) will be automatically sent to you each month
Select the "Auto Delivery" box at checkout.
Save Packages:
Save up to 20% & Free Shipping!
Purchase 3-5 bottles: save 5%
Purchase 6-11 bottles: save 12%
Purchase 12+ bottles: save 20%

phone

Menu
  • Products
    • Products A-Z
    • Dry Eye
    • Eye & Whole Body Health
      • OcularProtect® Robust Whole Body Formula
      • OcularEssentials® Whole Body Formula
    • Macular Health Concerns
      • MacularProtect Complete® AREDS-Based Formula & Multinutrient
      • MacularProtect® AREDS-Based Formula
    • Omega-3
    • Optic Nerve Health
    • Retinal Circulation
    • Bone & Joint Health
      • BoneProtect
      • JointProtect
  • Faqs
  • Resources
    • Staying Healthy Newsletter
    • EduFacts Newsletter
    • Product Monographs
    • Educational Links
  • About us
    • Company
    • Advisory Boards
    • Press Releases
    • In the News
    • Events
  • Contact
  • Login
  • View Cart
  • (0)
Facebook Twitter

Important Update on AREDS 2 Findings

ScienceBased Health - Education - EduFacts

The AREDS 2 Findings

On May 5th 2013, results from the AREDS2 clinical trial were presented at the ARVO annual meeting and published online in the Journal of the American Medical Association (JAMA).

In the first AREDS trial, supplementation with vitamins C and E, zinc, copper and beta-carotene reduced risk of AMD progression by 25%. In AREDS2, the investigators found no overall additional benefit from adding omega-3 fatty acids and/or lutein and zeaxanthin to the original formula. Importantly, however, an 18% reduced risk of developing advanced AMD was seen for those who received a beta-carotene free version of the AREDS formula plus lutein (10 mg) and zeaxanthin (2 mg).

An even greater, 26% reduction in risk for progression to advanced AMD was seen for those with low dietary intake of lutein and zeaxanthin (median 0.7 mg per day), who took an AREDS formula plus lutein and zeaxanthin compared to those with similar, low dietary intake who did not receive lutein and zeaxanthin. That finding is of striking public health importance since a substantial portion of Americans consume very little of these carotenoids.

AREDS 2 - The New Recommendations:

Below, Dr. Emily Chew summarized the the nutritional formula now recommended for those with intermediate to advanced age-related macular degeneration, based on the AREDS 2 findings:

Red lines indicate nutrients to exclude; gold text indicates a new formula addition:
AREDS 2 Recommendations: Vitamin C (500 mg) | Vitamin E (400 IU) | Lutein (10 mg) Zeaxanthin (2 mg) | Zinc (80 mg) | Copper (2 mg)

Dr. Emily Chew, presenting the AREDS2 findings at ARVO, pointed out that study participants were very well-nourished, and suggested that a greater reduction in AMD progression may have been demonstrated if the subjects’ diets had been more representative of the general U.S. population. Dietary intake of lutein and zeaxanthin for Americans is typically 1-2 mg per day. Additionally, Dr. Chew emphasized that beta-carotene was observed to suppress serum levels of lutein when these carotenoids were co-supplemented, due to their competitive absorption.

While no increased lung cancer risk was seen in those taking lutein and zeaxanthin, there was an association between beta-carotene and risk of lung cancer among former smokers. About half of AREDS2 participants were former smokers. Thus, the National Eye Institute now recommends adding lutein and zeaxanthin to the original formula and eliminating beta-carotene as a safer formulation for those with moderate to advanced AMD.

The trial also compared the effects of a lower dose of zinc (25 mg) with the original 80 mg administered in AREDS. A trend was seen that favored the high dose zinc for better protection against progression, though it did not reach significance. The authors conclude that there is insufficient data to make a new recommendation for zinc, and the NEI recommends that those with moderate to severe AMD continue to use the 80 mg dose. Importantly, no clinically or statistically significant differences in adverse effects (exacerbations in some GI and genitourinary conditions) were seen in the high versus low dose zinc groups.

Dr. Chew emphasized that the benefits of taking the original AREDS formula (with lutein and zeaxanthin, but no beta-carotene) apply to both the geographic atrophy and neovascular forms of AMD in those with moderate to advanced disease. Benefits of taking AREDS supplements are also long-lasting, according to Dr. Chew. An April, 2013 follow-up report in the journal Ophthalmology found that participants of the first AREDS trial taking the original antioxidant and zinc supplements, had a 25-30% reduced risk of developing advanced AMD over the next 5 years.

Looking Forward:
MacularProtect Complete-S - AREDS2 CompliantScienceBased Health’s MacularProtect Complete® AREDS2 reflects the NEI’s new recommendations, based on the AREDS 2 findings, in its levels of vitamins C, E, zinc, copper, lutein – and exclusion of beta-carotene. It includes 1 mg of zeaxanthin, which will be increased to the 2 mg tested in AREDS2 and available shortly. MacularProtect Complete AREDS2 includes a comprehensive multinutrient for whole body health. MacularProtect Complete AREDS2 is also available as a drink mix. MacularProtect® AREDS2, a stand-alone AREDS formulation, also reflects the AREDS 2 findings. For more information on SBH macular products, visit www.sbh.com or contact us for more information: [email protected] or 888-433-4726.

In a separate study, published online in JAMA Ophthalmology, AREDS2 also evaluated the effect of the various AREDS formulas on cataract. While none of the formulations helped reduce the risk of progression to cataract surgery, a subgroup of participants with low dietary lutein and zeaxanthin did gain some protection. In those with the poorest intake of lutein and zeaxanthin, there was a 32% reduction in progression to cataract surgery, a 30% reduction in development of any cataract, and a 36% reduction in the development of any severe cataract.


  • View a more in-depth discussion of the AREDS2 trial results in the May, 2013 SBH EduFacts newsletter

 

 

Home  > 

Stay Informed

Sign up to get nutrition news, health tips, and product updates.

Please also send me:
EduFacts scientific write-ups (monthly)
Notice of new products and special offers

Your information is never shared with third parties. View our privacy policy

Like Us on Facebook

Follow SBH on Facebook for great health tips, product info and much more.

Our Quality Guarantee

  • Products meet or exceed new GMPs
  • Produced in NSF®-certified facilities
  • Highest quality raw materials utilized
  • Third party testing
  • 30-day money-back guarantee (60 days for HydroEye)
Learn more »

Innovative Nutraceuticals for Eye Health

ABOUT SSL
CERTIFICATES

This site chose VeriSign SSL
for secure e-commerce and
confidential communications.

Home | Feedback | Manufacturing | Privacy Policy | Terms & Conditions | Contact Us

Call us Toll Free 1.888.433.4726. From Outside the US and Canada 281.885.7700
©ScienceBased Health

These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure or prevent any disease.

Top